United Kingdom · Question · Written question
UIN 201606
Voluntary Scheme for Branded Medicines Pricing and Access
Original
Introduced
13 October 2023
Last action
20 October 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
20 October 2023
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the cap mechanism in the Voluntary Scheme for Branded Medicines Pricing and Access on (a) levels of investment in late stage clinical trials a
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
13 October 2023
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the cap mechanism in the Voluntary Scheme for Branded Medicines Pricing and Access on (a) levels of investment in late stage clinical trials a
Source: Commons
20 October 2023
Answer
The Government has assessed the link between the cap mechanism in our medicine pricing schemes and various kinds of investment in our impact assessment of recent updates to the statutory scheme for branded medicines pricing, which operates alongside the v...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-10-13/201606
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1663753
- uk · wq-1663753 · source updated 20 October 2023